• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Quanterix Corporation (Amendment)

    2/14/24 8:25:48 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $QTRX alert in real time by email
    SC 13G/A 1 CamberQTRX13Ga2024.htm PRIMARY DOCUMENT  
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)
     
    Quanterix Corporation
    (Name of Issuer)
     
    Common Stock, $0.001 par value per share
    (Title of Class of Securities)
     
    74766Q101
    (CUSIP Number)
     
     
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☐ Rule 13d-1(b)
    ☒  Rule 13d-1(c)
    ☐ Rule 13d-1(d)
     
    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     
    Persons who respond to the collection of information contained in this form are not
    required to respond unless the form displays a currently valid OMB control number.
     
    13G
    CUSIP No. 74766Q101
    Page 2 of 6
     
                                                 
    1. Names of Reporting Persons.
    Camber Capital Management LP
    42-1693587
     
    2. Check the Appropriate Box if a Member of a Group
    (a) ☐
    (b) ☐
        3. SEC Use Only
    4. Citizenship or Place of Organization
    Delaware
       Number of Shares
       Beneficially
       Owned by
       Each Reporting
       Person With:
    5. Sole Voting Power
    0 shares
    6. Shared Voting Power
    0 shares
     
    7. Sole Dispositive Power
    0 shares
    8. Shared Dispositive Power
    0 shares
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    Camber Capital Management LP – 0 shares
        10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares       ☐
    11. Percent of Class Represented by Amount in Row (9)
    Camber Capital Management LP – 0%
    12. Type of Reporting Person
    Camber Capital Management LP – 00 (Limited Partnership)
     
    13G
    CUSIP No.    74766Q101
    Page 3 of 6

    1. Names of Reporting Persons.
    Stephen DuBois
    Not applicable
     
    2. Check the Appropriate Box if a Member of a Group
    (a) ☐
    (b) ☐
        3. SEC Use Only
    4. Citizenship or Place of Organization
    Stephen DuBois – United States
       Number of Shares
       Beneficially
       Owned by
       Each Reporting
       Person With:
    5. Sole Voting Power
    0 shares
    6. Shared Voting Power
    0 shares
    7. Sole Dispositive Power
    0 shares
    8. Shared Dispositive Power
    0 shares
    9. Aggregate Amount Beneficially Owned by Each Reporting Person
    Stephen DuBois – 0 shares
       10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares       ☐
    11. Percent of Class Represented by Amount in Row (9)
    Stephen DuBois – 0%
    12. Type of Reporting Person
    Stephen DuBois – IN
     
    13G
      CUSIP No.     74766Q101
    Page 4 of 6
     
     
     
    ITEM 1.
    (a) Name of Issuer:
    Quanterix Corporation
     
    (b) Address of Issuer's Principal Executive Offices:
    900 Middlesex Turnpike Billerica, MA 01821
     
    ITEM 2.
    (a) Name of Person Filing:
    Camber Capital Management LP
    Stephen DuBois
     
    (b) Address of Principal Business Office, or if None, Residence:
    Camber Capital Management LP
    Stephen DuBois
    101 Huntington Avenue
    Suite 2101
    Boston, MA 02199
     
    (c) Citizenship:
    Camber Capital Management LP – Delaware
    Stephen DuBois – United States
     
    (d) Title of Class of Securities:
    Common Stock, $0.001 par value per share
     
    (e) CUSIP Number:
    74766Q101
     
     
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
     
     
    (a)
    [_]
    Broker or dealer registered under Section 15 of the Act  (15 U.S.C. 78o).
     
    (b)
    [_]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).   
     
    (c)
    [_]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).   
     
    (d)
    [_]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
     
    (e)
    [_]
    An investment adviser in accordance with  ss.240.13d-1(b)(1)(ii)(E);   
     
    (f)
    [_]
    An employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F);   
     
    (g)
    [_]
    A parent holding company or control person in accordance with ss.240.13d-1(b)(1)(ii)(G);   
     
    (h)
    [_]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);   
     
    (i)
    [_]
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);   
     
    (j)
    [_]
    Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).
     
    ITEM 4. OWNERSHIP.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
     
    (a) Amount beneficially owned: Camber Capital Management LP – 0 shares
    Stephen DuBois – 0 shares
     
    (b) Percent of class: Camber Capital Management LP – 0% 
    Stephen DuBois – 0%
     
     
    13G
       CUSIP No.    74766Q101
    Page 5 of 6
     
    (c) Number of shares as to which such person has:
     
    (i) Sole power to vote or to direct the vote
    Camber Capital Management LP – 0 shares
    Stephen DuBois – 0 shares
     
    (ii) Shared power to vote or to direct the vote
    Camber Capital Management LP – 0 shares
    Stephen DuBois – 0 shares
     
    (iii) Sole power to dispose or to direct the disposition of
    Camber Capital Management LP – 0 shares
    Stephen DuBois – 0 shares
     
    (iv) Shared power to dispose or to direct the disposition of
    Camber Capital Management LP – 0 shares
    Stephen DuBois – 0 shares
     
     
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [x].
     
     
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
     
    Not applicable
     
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
     
    Not applicable

    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
     
    Not applicable
     
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
     
    Not applicable
     
     
    13G
    CUSIP No.    74766Q101
    Page 6 of 6
     
     
     
    ITEM 10. CERTIFICATIONS.
    The following certification shall be included if the statement is filed pursuant to S.240.13d-1(c):
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.
     
     
     
    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    CAMBER CAPITAL MANAGEMENT LP
    By: /s/Sean George
    Sean George
    Chief Financial Officer
     
    STEPHEN DUBOIS
    By: /s/ Stephen DuBois
    Stephen DuBois, individually
     
    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.
     
     
    Get the next $QTRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QTRX

    DatePrice TargetRatingAnalyst
    2/1/2024$30.00Sector Outperform
    Scotiabank
    9/25/2023$25.00 → $32.00Hold → Buy
    Canaccord Genuity
    8/8/2023$30.00Market Perform → Outperform
    SVB Securities
    5/23/2023$13.00 → $27.00Neutral → Buy
    Goldman
    8/15/2022$40.00 → $12.00Buy → Hold
    Canaccord Genuity
    8/9/2022$38.00 → $18.00Outperform → Market Perform
    Cowen
    8/9/2022$35.00 → $15.00Outperform → Mkt Perform
    SVB Leerink
    3/2/2022$85.00 → $60.00Overweight
    JP Morgan
    More analyst ratings

    $QTRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kent Lake Condemns Quanterix's Failure to Schedule Its 2025 Annual Meeting as a Tactic to Silence Shareholders

      RINCON, Puerto Rico, June 11, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), today issued the following statement condemning the Company's failure thus far to schedule its 2025 Annual Meeting on time. "Quanterix's ongoing failure to schedule its 2025 Annual Meeting until the approaching legal deadline is consistent with the Board's pattern of limiting and disregarding shareholder input. More than one year has already passed since Quanterix held its last Annual Meeting on June 3, 2024, yet the 2025 Annual Meeting remains unscheduled. We believe the Board

      6/11/25 8:00:00 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix to Present at Goldman Sachs Global Healthcare Conference

      Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, Florida on Monday, June 9th, at 1:20 p.m. ET. Quanterix will also host one-on-one meetings with institutional investors during the conference. Webcast Information The live webcast presentation can be accessed from the Investors section of the company's website at www.quanterix.com. A replay of the webcast will be available for a limited period following the conference. To learn more about Quanterix, visit www.qu

      6/6/25 9:41:00 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal

      RINCON, Puerto Rico, May 23, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), today issued the following statement regarding the Company's Post-Effective Amendment to its S-4 registration statement and Akoya Biosciences' ("Akoya") (NASDAQ:AKYA) disclosure of an unsolicited all-cash offer at $1.40-per-share. "Quanterix's amended merger terms (the "Amended Merger Agreement"), structured to avoid a shareholder vote, already commit the company to pay $20 million in cash alongside 8.4 million newly issued shares in its misguided pursuit of Akoya. On May 20, 20

      5/23/25 2:21:00 PM ET
      $AKYA
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Scotiabank initiated coverage on Quanterix with a new price target

      Scotiabank initiated coverage of Quanterix with a rating of Sector Outperform and set a new price target of $30.00

      2/1/24 6:32:54 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix upgraded by Canaccord Genuity with a new price target

      Canaccord Genuity upgraded Quanterix from Hold to Buy and set a new price target of $32.00 from $25.00 previously

      9/25/23 9:03:48 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix upgraded by SVB Securities with a new price target

      SVB Securities upgraded Quanterix from Market Perform to Outperform and set a new price target of $30.00

      8/8/23 6:29:03 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Walt David R bought $984,968 worth of shares (160,000 units at $6.16), increasing direct ownership by 9% to 1,866,933 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      6/13/25 4:39:15 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • President & CEO Toloue Masoud bought $248,723 worth of shares (45,900 units at $5.42), increasing direct ownership by 10% to 518,922 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      6/10/25 4:08:44 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Walt David R bought $1,133,796 worth of shares (210,000 units at $5.40), increasing direct ownership by 14% to 1,706,933 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      6/9/25 5:44:04 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Walt David R bought $984,968 worth of shares (160,000 units at $6.16), increasing direct ownership by 9% to 1,866,933 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      6/13/25 4:39:15 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • President & CEO Toloue Masoud bought $248,723 worth of shares (45,900 units at $5.42), increasing direct ownership by 10% to 518,922 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      6/10/25 4:08:44 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Walt David R bought $1,133,796 worth of shares (210,000 units at $5.40), increasing direct ownership by 14% to 1,706,933 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      6/9/25 5:44:04 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    SEC Filings

    See more
    • SEC Form EFFECT filed by Quanterix Corporation

      EFFECT - Quanterix Corp (0001503274) (Filer)

      6/13/25 12:15:03 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form POS AM filed by Quanterix Corporation

      POS AM - Quanterix Corp (0001503274) (Filer)

      6/3/25 9:24:17 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SD filed by Quanterix Corporation

      SD - Quanterix Corp (0001503274) (Filer)

      6/2/25 4:50:04 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    Leadership Updates

    Live Leadership Updates

    See more
    • SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

      SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

      3/19/25 4:10:00 PM ET
      $EXAS
      $QTRX
      $SERA
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix Expands Capabilities with Strategic Acquisition of EMISSION

      Builds technology capabilities through vertical integration of proprietary bead technology and drives OEM business Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the acquisition of EMISSION iNC. ("EMISSION"). Quanterix expects the transaction will close in January 2025. "As we expand our technology stack toward higher multi-plex and multi-omic capabilities, it is imperative we control core components," said Masoud Toloue, Chief Executive Officer of Quanterix. "EMISSION's proprietary bead technology has already been validated on our upcoming new Simoa platform and will en

      12/17/24 6:59:00 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix Welcomes Ivana Magovčević-Liebisch, Ph.D., J.D. to Board of Directors

      Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the appointment of Ivana Magovčević-Liebisch, Ph.D., J.D. to its Board of Directors. Dr. Magovčević-Liebisch brings more than 25 years of biopharmaceutical industry experience, including founding Vigil Neuroscience, Inc. four years ago, where she serves as President and Chief Executive Officer. Under her leadership, Vigil raised more than $350 million and advanced its lead pipeline candidates into clinical development, including the first clinical-stage small molecule TREM2 agonist for the potential treatment of Alzheimer's dis

      10/2/24 4:00:00 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Quanterix Corporation

      SC 13G/A - Quanterix Corp (0001503274) (Subject)

      11/13/24 12:41:46 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Quanterix Corporation

      SC 13G - Quanterix Corp (0001503274) (Subject)

      6/27/24 2:46:59 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Quanterix Corporation (Amendment)

      SC 13G/A - Quanterix Corp (0001503274) (Subject)

      2/14/24 4:57:53 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    Financials

    Live finance-specific insights

    See more
    • Quanterix Releases Financial Results for the First Quarter of 2025

      Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2025. "During a time when market resource constraints threaten to slow scientific progress, we remain committed to keeping the innovation engine moving forward," said Masoud Toloue, CEO of Quanterix. "Today, we are excited to announce a major advance: through a new early-access program, Simoa® ONE assay kits will become compatible with over 20,000 existing flow cytometers worldwide—significantly reducing the need for capital equipment purchases by current and future customers. This leap is enabled by

      5/12/25 4:01:00 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix To Report First Quarter 2025 Financial Results on May 12, 2025

      Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Monday, May 12, 2025, at 4:30 p.m. E.T., to discuss its first quarter 2025 financial results. Quanterix will issue a press release regarding its first quarter 2025 financial results prior to the conference call on Monday, May 12, 2025, after the market closes. The press release will be posted on the Quanterix website at https://www.quanterix.com/. To listen to the live conference call, investors can dial (800) 715-9871 or (646) 307-1963 and enter conference ID 7353673. Interested investors can also access the live we

      5/5/25 7:00:00 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix Releases Financial Results for the Fourth Quarter of 2024

      Delivers seventh consecutive quarter of double-digit revenue growth Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the fourth quarter ended December 31, 2024. "During the fourth quarter, we delivered 11% revenue growth, our seventh straight quarter of double-digit growth, despite a capital constrained environment," said Masoud Toloue, Chief Executive Officer of Quanterix. "Our ability to grow in a difficult environment is the result of investments in our business model, which focuses on key vertical markets and recurring revenues. We are expanding our approach to immunology and

      3/17/25 4:01:00 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials